US Dollar Slips as Weak Retail Sales Reduce Fed Rate Hike Bets 
Canada-US Trade Talks Gain Momentum Ahead of Aug. 19 Tariff Deadline 
Oil Prices Slide as OPEC, IEA Cut 2026 Demand Forecasts 
China Automakers Accelerate Global Expansion as Domestic Car Sales Slump 
Wall Street Hits Record High as Softer Inflation Data Eases Fed Rate Hike Fears 
Gold Prices Slip From Two-Month High as Inflation and Fed Outlook Drive Markets 
Trump Imposes New Tariffs on Drone Imports Over US Security Concerns 
UK Economy Posts Surprise June Growth as World Cup and Hot Weather Lift Activity 
Japan Government Backs Earlier BOJ Rate Hike as Inflation Pressures Build 
Gold Prices Slip From 10-Week High as Fed and Hormuz Risks Shape Outlook 
Gold Prices Retreat From Two-Month High as Softer Inflation Eases Fed Rate Hike Bets 
European Stocks Steady as U.S.-Iran War, Euro Zone Data Keep Investors Cautious 
S&P 500 Retreats From Record High as AI Stocks Slide, Retail Sales Disappoint 
Oil Prices Fall as U.S. Crude Inventories Surge and Hormuz Tensions Persist 
Strait of Hormuz Shipping Near Standstill After New Vessel Attacks 
Asian Stocks Rally as Cooling US Inflation Boosts Fed Rate Outlook 
Asian Currencies Steady Ahead of US CPI as Oil Prices Rise 
Add as a preferred source on Google
Activist investor Starboard Value has acquired a $1 billion stake in Pfizer to push for strategic changes in the U.S. pharmaceutical giant. This investment comes as Pfizer contends with declining sales of its COVID-19 vaccines and treatments, underwhelming sales for its RSV vaccine, and failed clinical trials for an obesity medication.
Former Pfizer Executives to Aid Starboard’s Efforts
Starboard has approached Ian Read, Pfizer’s CEO until 2019, and Frank D’Amelio, who served as CFO until 2021. Both former executives are interested in helping Starboard steer the company toward renewed growth.
Stock Price Decline Post-COVID Success
Albert Bourla, who became CEO in 2019, was key in partnering with BioNTech to develop Pfizer's COVID-19 vaccine. However, as pandemic demand wanes, the company’s stock has plummeted from approximately $41 to $28.58 as of last Friday, reflecting concerns over weakened vaccine demand and disappointing new product launches.
Aggressive Acquisitions Draw Scrutiny
Since 2020, Pfizer has made over $70 billion in acquisitions, including major deals like Seagen for $43 billion, Biohaven for $13 billion, Arena for $6 billion, Global Blood Therapeutics for $5 billion, and Trillium for $2 billion. The acquisitions have raised investor concerns, especially regarding GBT’s sickle cell drug, which faced market withdrawal due to severe side effects and discontinuation of related studies.
Starboard’s History of Corporate Overhauls
Known for pushing changes in major companies like News Corp, Salesforce, and Match Group, Starboard Value's influence could lead to significant shifts in Pfizer's strategic direction.
The Wall Street Journal first reported Starboard’s Pfizer stake. Neither Pfizer nor Starboard has officially commented on the investment or potential next steps.
